^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1361849

    i
    Associations
    News

    Trials

    Company:
    CureVac
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC (NCT03164772)
    Phase 1/2
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    12/20/2017
    Primary completion :
    10/29/2021
    Completion :
    10/29/2021
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849 • self-amplifying RNA cancer vaccine